Shaare Zedek Medical Center and Arieli Capital Announce the Establishment of the Shaare Zedek Arieli Innovation Hub - SHAAR
19 Dec 2023
Healthcare Innovation Hub to focus on transformative startups, advancing innovative technologies and supporting pioneering research and development that will benefit humanity
JERUSALEM and NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Shaare Zedek Medical Center (SZMC), Jerusalem's largest multi-disciplinary medical center, and Arieli Capital, LLC (Arieli), a global multifaceted investment firm, today announced the creation of the Shaare Zedek Arieli Innovation Hub, SHAAR. This landmark center is set to become a cornerstone hub for healthcare innovation.
Shaare Zedek Scientific (SZS), the research and innovation arm of SZMC, and Arieli are leading the new SHAAR Hub, which was launched with support from the Jerusalem Development Authority (JDA). SHAAR, located within the Shaare Zedek Medical Center, combines SZMC's medical expertise and world-class facilities with Arieli's investment experience and track record of fostering innovation and growth platforms.
SHAAR's mission is to build a gateway between innovation and capital, creating an environment where cutting-edge medical research, pioneering projects, and forward-thinking startups can thrive through strategic financial and professional support, leading co-working space and a collaborative community. The hub facilitates advanced innovation programs and access to investment and funding opportunities, providing startups and medical projects with the resources needed to turn visionary healthcare ideas into impactful solutions.
United with Ariel's strong focus on fostering innovation, business and financial growth, SHAAR is where startups, investors, medical professionals and industry leaders unite to advance and support the next generation of healthcare technologies and entrepreneurs.
"SHAAR, Hebrew for Gateway, is a true embodiment of our mission," Prof. Ofer Merin, CEO of SZMC, explained. "Our goal is to equip entrepreneurs with direct access to physicians, clinical settings, data and samples. Such access is essential, serving as a springboard for the development of innovative medical solutions. I have no doubt that this significant partnership with Arieli Capital, led by Prof. Dan Turner and Dr. Renana Ofan, will greatly contribute to the success of this initiative."
"We are honored to partner with the Shaare Zedek Medical Center to bring the important mission of SHAAR to life," said Evan Renov, Co-Founder and Chief Executive Officer of Arieli. "We are eager to bring Arieli's global business expertise in growing healthcare startups to SHAAR. Our goal is to bridge the gap between promising entrepreneurs and the venture capital industry, ultimately impacting people's lives and healthcare on a global scale."
SHAAR plans to launch an open call for companies by year's end, targeting worldwide market-ready healthcare startups, to participate in the first SHAAR Scale-up cohort.
About SHAAR:
Founded by Shaare Zedek Medical Center and Arieli Capital, SHAAR's mission is to build a gateway between innovation and capital, creating an environment where cutting-edge medical research, pioneering projects, and forward-thinking startups can thrive through strategic financial and professional support. The hub facilitates advanced innovation programs and access to investment and funding opportunities, providing startups and medical projects with the resources needed to turn visionary healthcare ideas into impactful solutions. SHAAR, located within the Shaare Zedek Medical Center, combines SZMC's medical expertise and world-class facilities with Arieli's investment experience and track record of fostering innovation and growth platforms. For more information, please visit www.shaarhealth.com.
About Shaare Zedek Medical Center:
Shaare Zedek Medical Center (SZMC) is the largest multi-disciplinary medical center in Jerusalem, treating nearly 1,000,000 patients annually in 30 inpatient departments and 70 ambulatory care units. With a constant commitment to improve and provide our patients with the best possible care, the 1000-bed facility and staff of over 4,500 people is dedicated to combining compassionate medical care with a constant attention to groundbreaking scientific research and technological development to benefit the advancement of medicine in Israel and around the world. For more information, please visit www.szmc.org.il/en.
About Shaare Zedek Scientific:
Shaare Zedek Scientific Ltd. (SZS) is the research and innovation arm of Shaare Zedek Medical Center, Jerusalem's fastest-growing major medical center. Our goal is to act as an innovation bridge between leading companies in the fields of medical research and our hospital. Madait's strength is in converting initial research initiatives into novel medical treatments by leveraging our hospital's abilities, facilities, patients, and team expertise for the advancement of medical science. Our daily mission is to ensure that Shaare Zedek's growing successes in research and clinical care also benefits the global healthcare community. For more information, please visit www.madait.co.il.
About Arieli Capital:
Arieli Capital (Arieli) is a multifaceted investment firm that is an active investor and partner in the next generation of technology companies. Arieli Capital continuously strives to identify and support companies creating real impact while keeping financial returns as the primary objective. Arieli is a recognized global leader in innovation. Arieli creates and operates global innovation programs across governmental, academic and corporate partnerships. For more information, please visit www.arielicapital.com.
Forward-Looking Statements
This release contains forward-looking information about Arieli Capital LLC ("Arieli") which involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Accordingly, any statements included in this communication are not statements of historical facts but may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements are, in some cases, accompanied by words such as "may," "should," "would," "could," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "seem," "seek," "continue," "future," "will," "expect," "outlook" or other similar words, phrases or expressions and the negatives of such words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding Arieli's expectations of future events, future opportunities, global expansion and other growth initiatives, and Arieli's investments in such initiatives. These statements are based on various assumptions and known or unknown risks, uncertainties and other factors, and actual results may differ materially. Neither Arieli nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Arieli assumes no obligation to update any forward-looking statements or information contained in this communication except to the extent required by law.
Contact:
Arieli Capital, LLC
Nataf Dgani, Head of Marketing
+972-54-757-3384; [email protected]
Nurit Kantarovich, VP Strategic Partnerships
+972-544416834; [email protected]
Maya Karvat, Public Relations
+972-50-575-7817; [email protected]
Shaare Zedek Medical Cener
Yossi Gottesman, Spokesperson
+972-50-312-1842; [email protected]
Renana Ofan, CEO, Shaare Zedek Scientific
+972 54-652-1911; [email protected]
SOURCE Arieli Capital; Shaare Zedek Medical Center
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.